Author: sHq_LoGiNz

WASHINGTON, June 4, 2026 /3BL/ – The Asthma and Allergy Foundation of America (AAFA), the International Facility Management Association (IFMA) and the International WELL Building Institute (IWBI) today honored the Advanced Research Projects Agency for Health (ARPA-H) with a Leadership in Innovation Award recognizing the agency’s pioneering efforts to bridge innovation, public health and the built environment through breakthrough research and development (R&D) in healthy indoor air.

“Americans spend 90% of their lives indoors, breathing air that can be two to five times more polluted than what’s outside, yet federal investment in indoor air quality has never matched the scale of the problem,” said Kenneth Mendez, President and CEO of AAFA. “ARPA-H is changing that. BREATHE and PRO-MICROBE represent the kind of bold, patient-centered innovation that millions of Americans living with asthma and allergies have been waiting for, and AAFA is proud to recognize ARPA-H for this important work.”

The award honors ARPA-H for its groundbreaking work through its BREATHE and PRO-MICROBE programs — two bold R&D initiatives helping to revolutionize how indoor environments are understood, monitored and optimized to protect and enhance human health. Together, the programs are advancing next-generation technologies designed to continuously measure indoor air quality, estimate health risks in real time and support interventions that promote cleaner, healthier indoor environments.

“Optimizing our buildings for health is one of the single greatest public health opportunities of our time,” said Rachel Hodgdon, President and CEO of IWBI. “We are excited to recognize ARPA-H for serving as a massive accelerant to meet this moment. Their groundbreaking work is driving the market to transform indoor air quality to not only prevent airborne illness, but actively extend human health span, boost cognitive performance and deliver well-being at scale.”

By accelerating innovations that can help prevent illness, improve well-being and enhance longevity, the ARPA-H programs hold enormous promise for children with asthma and allergies, adults with COPD, hospitalized patients and other vulnerable populations. The initiatives are also helping position the United States as a global leader in the rapidly expanding healthy buildings sector — driving innovation that supports human performance, productivity, resilience and long-term economic competitiveness.

“It is well understood across the building sector that operations and maintenance have a significant impact on the health, safety and productivity of building occupants throughout the built environment,” said Michael V. Geary, CAE, President and CEO of IFMA. “We congratulate ARPA-H and thank them for their leadership in advancing tools and research that are invaluable to facility managers around the globe.”

The award was presented to ARPA-H leadership today during ARPA-H’s Healthy Buildings Demo Day in Washington, D.C., where project awardees showcased hands-on demonstrations highlighting cutting-edge innovations aimed at transforming indoor air quality, advancing healthier buildings and strengthening public health.

“We estimate poor indoor air quality drives over $180 billion in healthcare costs each year in this country. That’s unacceptable,” said ARPA-H Director Alicia Jackson, Ph.D. “That massive impact on the American people demands an innovative, flexible solution we can roll out in years—not decades. With BREATHE and PRO-MICROBE, ARPA-H is redefining what’s possible in the built environment to protect every American from respiratory illnesses and the respiratory effects of chronic conditions.”

“Parents shouldn’t have to send their kids to school worrying the environment could exacerbate asthma, and patients shouldn’t have to enter a hospital just to leave with a new airborne illness,” said ARPA-H BREATHE and PRO-MICROBE Program Manager Jessica Green, Ph.D. “I’m incredibly proud of the rapid progress our awardees have made. We are headed toward a new era in indoor air quality that will translate to healthier kids, safer patients, dramatic cost savings, and far greater peace of mind.”

About the Asthma and Allergy Foundation of America
Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and improving the quality of life for people affected by asthma and allergic diseases through support, advocacy, education, and research. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of regional chapters, and collaborations with community-based groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the first asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit: aafa.org and kidswithfoodallergies.org.

About the International Facility Management Association
Founded in 1980, the International Facility Management Association (IFMA) is the world’s largest, most widely recognized association for facility management (FM) professionals. Supporting more than 25,000 members in 140 countries, IFMA’s Vision is to lead the future of the built environment to make the world a better place. IFMA is a key contributor to the development of international FM standards and works with decision makers to inform FM-related policy. IFMA provides career resources and continuing education, offers three industry-respected credentials, maintains the largest repository of FM-related content on the web and hosts year-round global events. Learn more at ifma.org.

About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the global authority for transforming health and well-being in buildings, organizations and communities. In pursuit of its public-health mission, IWBI mobilizes its community through the development and administration of the WELL Building Standard (WELL), WELL for residential, WELL Community Standard, its WELL ratings and management of the WELL AP credential. IWBI also translates research into practice, develops educational resources and advocates for policies that promote people-first places for everyone, everywhere. More information on WELL can be found here.

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL EP, WELL Score, The WELL Conference, We Are WELL, the WELL Community Standard, WELL Health-Safety Rated, WELL Performance Rated, WELL Equity Rated, WELL Equity, WELL Coworking Rated, WELL Residence, Works with WELL, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

Media contact:
media@wellcertified.com

View original content here.

As part of the Entertainment Industry College Outreach Program’s (EICOP) HBCU in LA Summit Week, AEG, the leading sports and live entertainment company, hosted more than 40 interns from Historically Black Colleges and Universities (HBCUs) at its L.A. LIVE campus on May 29, 2026.

The event brought industry talent and executives from AEG and across the entertainment sector together and offered students a chance to participate in panel discussions, mentoring sessions and learn first-hand about jobs in the sports and live event industry.

The day kicked off with lunch at L.A. LIVE where students were able to meet AEG employees representing the Talent Acquisition team, Black Equity Employee Network Group and Goldenvoice Black. Afterwards the students received a behind-the-scenes tour of Crypto.com Arena and concluded with a networking session with various AEG business units and EICOP partners at Peacock Theater.

The Entertainment Industry College Outreach Program is a non-profit educational arts workforce development organization, dedicated to educating, training, and recruiting the best and brightest student leaders from our nation’s Historically Black Colleges, Universities and other Minority Serving Institutions for careers across all aspects of the entertainment, music, sports, gaming and tech industries. Click here to learn more about the organization.

Cascale recently attended Move! Sustainability Fashion Summit 2026 in Madrid, Spain, bringing together approximately 250 professionals from across the textile, apparel, and footwear industry to explore the future of circularity, textile waste, business resilience, and sustainability.

Key Takeaways

• Sustainability is increasingly being viewed as a compliance requirement rather than a competitive differentiator.
• Fragmented data systems and limited infrastructure continue to slow progress toward circularity.
• Collaboration across the value chain remains essential to addressing textile waste and scaling solutions.

Across sessions and discussions, a clear theme emerged: sustainability is increasingly shifting from a strategic differentiator to a business requirement driven by evolving regulations. Industry leaders highlighted the growing need for collaboration, harmonized data systems, and scalable solutions to address some of the sector’s most pressing challenges.

Speakers from organizations including H&M, the Ellen MacArthur Foundation, ReHubs, Pangaia, and the Regenerative Fund for Nature shared perspectives on circular business models, post-consumer textile waste, regenerative production systems, and the infrastructure needed to support industry-wide transformation.

Several discussions focused on the significant gap between circularity ambitions and current operational realities. While brands continue to invest in resale, collection, and recycling initiatives, speakers acknowledged ongoing challenges related to traceability, data fragmentation, and limited recycling capacity. Industry experts also emphasized that textile-to-textile recycling remains below one percent globally, underscoring the scale of the work ahead.

Roundtable conversations explored the relationship between sustainability investment and business performance, with speakers noting ongoing challenges in building the broader financial case. Participants also noted that consumers continue to prioritize quality, design, and value, with sustainability increasingly viewed as an expected baseline rather than a primary purchasing driver.

For Cascale, the discussions reinforced several priorities already shaping our work. Industry collaboration, consistent and credible sustainability data, and harmonized measurement tools are essential in supporting meaningful progress across the value chain.

GALWAY, Ireland, June 4, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, today announced its first cohort of Medtronic Spark Scholarship recipients, recognizing 100 exceptional students from low-income households pursuing careers in health tech. This marks a significant milestone in Medtronic Spark’s global 10-year initiative to propel 1 million students into health tech careers.

The inaugural scholarship cohort represents 12 home countries and was selected from a pool of more than 1,500 applicants across 42 countries. Each recipient receives:

• Financial support for educational expenses, renewable for up to four years
• Career building experiences, which may include Medtronic mentorship, coaching, networking support, and more
• Availability of an emergency support fund to close the gap when facing unexpected episodic hardships that can derail academic progress

“The Medtronic Spark Scholarship gives students from around the world an opportunity to pursue their passion for improving people’s lives,” said Dr. Sally Saba, President of Medtronic Foundation. “I’m inspired and humbled by their stories of grit, perseverance, and determination to seek an education that allows them to serve and heal others. By combining financial support with mentorship, career guidance, and additional services, we’re creating a holistic support system that removes barriers and empowers students to graduate and thrive in health tech careers.”

“I’m inspired by the challenge of turning breakthrough science into technologies people can trust, access, and benefit from,” said Nathan, a Medtronic Spark scholarship recipient studying biomedical engineering and finance at Washington University in St. Louis. “I hope to build and scale health innovations—especially in areas like neurotechnology.”

Medtronic will award up to 100 new scholarships each year over the next 10 years to students residing in 70+ eligible countries. Applications will re-open in October 2026.

“I have always dreamed of helping people in difficult situations achieve a better quality of life through science,” said Valeria, a Medtronic Spark scholarship recipient at the Instituto Teccnológico y de Estudios Superiores de Monterrey in Mexico. “Receiving the Medtronic Spark scholarship motivates me to continue pursuing this dream, to move forward with determination along the career path I am passionate about.”

Visit https://www.medtronicspark.com/scholarship/ to learn more and sign up to receive updates.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Justin Paquette
Public Relations
+1-612-271-7935

Ingrid Goldberg
Investor Relations
+1-763-505-2696

Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States 

• New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi
• New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood
• Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae

INDIANAPOLIS, June 4, 2026 /3BL/ – Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i

The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii

“New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods,” said Jeff Simmons, President and CEO, Elanco Animal Health. “We want to thank the FDA, EPA and USDA, for all their work to prepare for this threat. We’re committed to supporting our customers during this challenging time by delivering innovation, scientific expertise, and available resources to help treat New World screwworm and support the health and well-being of animals.”

With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, Elanco is working alongside the U.S. animal health industry to help them fight against this parasite, offering a portfolio of options for pets and livestock that can help treat New World screwworm larvae infestations.

Available Elanco Treatment and/or Prevention Options 

Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile. They will be distributed in coordination with state animal health officials and federally recognized tribal agencies. In the near future, APHIS will share additional information about the requirements for use, including tracking and reporting requirements and required safety and personal protective equipment.

As New World screwworm enters the United States, Elanco is committed to working alongside producers as they continuously evolve management practices and to help them implement prevention and treatment protocols to use the right product at the right time.

To learn more about Elanco’s ongoing efforts and historical perspective on New World screwworm, please visit our previous coverage:

• Elanco’s Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock 
• Elanco’s Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs 
• Elanco’s Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats 
• Elanco’s Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs 

To learn more about New World screwworm (NWS) using the following resources:

• USDA NWS Alert and Fact Sheet 
• NCBA NWS Resources 
• FDA Information for Veterinarians on NWS 

i USDA Confirms Presence of New World Screwworm in the United States | Animal and Plant Health Inspection Service 
ii “New World Screwworm.” www.aphis.usda.gov, www.aphis.usda.gov/livestock-poultry-disease/cattle/ticks/screwworm.

PM-US-26-1137

About Elanco Animal Health 
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Indications for Credelio Quattro/Credelio Quattro-CA1 
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

Important Safety Information for Credelio Quattro/Credelio Quattro-CA1 
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

Emergency Use Authorization of Credelio (lotilaner) Chewable Tablets for New World Screwworm (NWS) 

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) chewable tablets for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Credelio is not approved for this use.

Credelio (lotilaner) is approved for other uses in dogs and puppies.

For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.

Limitations of Authorized Use 
Credelio (lotilaner) chewable tablets is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) chewable tablets under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio 
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Important Safety Information for Credelio 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS) 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.

Credelio CAT is approved for other uses.

For additional information on the EUA, please refer to the Credelio Cat NWS Fact Sheet.

Limitations of Authorized Use 
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio CAT 
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater.

Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater.

Important Safety Information for Credelio CAT 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian.

Emergency Use Authorization of Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for New World Screwworm (NWS)

WARNING: Neurotoxicity. Read full Fact Sheet for complete information.

• Coumaphos and propoxur can cause neurotoxicity. May be fatal if swallowed. May be fatal if inhaled. Harmful if absorbed through skin. Causes moderate eye irritation. Do not breathe dust. Avoid contact with eyes, skin, or clothing.
• Use only with appropriate personal protective equipment (PPE): coveralls worn over long-sleeve shirt and long pants, shoes, socks, and protective eyewear; chemical-resistant gloves made of barrier laminate, butyl rubber (≥ 14 mils), nitrile rubber (≥14 mils), neoprene rubber (>14 mils), natural rubber (≥14 mils), polyethylene, polyvinyl chloride (PVC) ≥14 mils, or Viton (>14 mils); and a minimum of a NIOSH-approved elastomeric half mask respirator consisting of protection factor (PF) 10 fitted with organic vapor (OV) cartridges and combination R or P filters; or a NIOSH-approved gas mask with OV canisters; or a NIOSH-approved powered air purifying respirator with OV cartridges and combination HE filters.
• This product is toxic to mammals, birds, fish, and aquatic invertebrates.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product Negasunt Powder for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia homnivorax) larvae (myiasis) in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. Negasunt Powder is not approved for this use.

For use by employees of federal, state, local, and federally recognized tribal agencies, and persons working under their authority and at their direction. Also for use by or on the order of a licensed veterinarian in NWS infested zones and adjacent surveillance zones as defined by the U.S. Department of Agriculture (USDA).

For additional information on the EUA and for complete safety information, please refer to the Negasunt Powder NWS Fact Sheet.

Limitations of Authorized Use 
It is a violation of federal law to use this drug product other than as directed in the authorized Fact Sheet.

Treated animals must not be slaughtered for human consumption within 28 days of the last treatment.

A milk discard time has not been established for this product; do not use in animals producing milk for human consumption.

A withdrawal period has not been established for this product in pre-ruminating calves; treated calves and calves born to treated cows must not be processed for veal.

Do not use in horses intended for human consumption. Do not use in domestic indoor pets (e.g., dogs, cats, rodents, rabbits) nor in residences. Do not use in birds. Do not use in free-ranging wildlife.

To avoid overexposure, each individual person cannot treat more than 3 large wounds (>2 inches diameter) a day or more than 30 small superficial wounds (≤2 inches diameter) a day (or an equivalent thereof) with Negasunt Powder or any other coumaphos-containing products.

Negasunt Powder is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

Federal law prohibits the extra-label use of this drug.

Additional Important Safety Information 
Not for use in humans. Keep out of reach of children. Only handlers wearing required PPE may be in the area during application. Do not apply in a confined, non-ventilated area; provide thorough ventilation. Call a poison control center or doctor immediately for treatment advice if Negusant Powder is swallowed, inhaled, on skin or clothing, or in eyes. Sulfonamides are contraindicated in animals that are hypersensitive to them and in animals with severe renal or hepatic impairment. For external use only on animals. Do not contaminate water, feed, troughs, feed handling equipment, or milk or meat handling equipment. Use with caution in very young, weak, or debilitated animals. In the case of overdose, treat with atropine sulfate or pralidoxine chloride (2-PAM) as soon as possible. The most common adverse reactions associated with organophosphate and carbamate toxicity in animals include frequent urination and defecation, muscle twitching, and watering eyes.

Important Information about Tanidil 
Tanidil™ is an unregistered product for distribution and use only under a Section 18 emergency exemption. The Section 18 labeling must be in the possession of the user at the time of pesticide application. This product may only be used to prevent or control New World screwworm in and on animal wounds on labeled animal host species.

For use only by federal, state, local, and federally recognized tribal agencies, and persons working under their supervision; personnel at quarantine stations and areas; veterinarians; veterinarians or certified applicators at livestock and game facilities, zoos, wildlife facilities, animal rehabilitation centers; and wildlife professionals.

Read the entire label. This product must be used strictly in accordance with this label’s precautionary statements and use directions, as well as with all applicable state and federal laws and regulations. Please visit the Tanidil fact sheet for more information.

Use Period: This exemption is effective on April 27, 2026 and expires on April 27, 2029. No applications of Tanidil may be made under the emergency exemption before its effective date or after its expiration date.

Credelio, Credelio Quattro, Negasunt, Tanidil, Catron, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates 
 

Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States 

• New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi
• New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood
• Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae

INDIANAPOLIS, June 4, 2026 /3BL/ – Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i

The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii

“New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods,” said Jeff Simmons, President and CEO, Elanco Animal Health. “We want to thank the FDA, EPA and USDA, for all their work to prepare for this threat. We’re committed to supporting our customers during this challenging time by delivering innovation, scientific expertise, and available resources to help treat New World screwworm and support the health and well-being of animals.”

With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, With more than 70 years of animal health experience, including helping mitigate, prevent and treat New World screwworm in other parts of the world, Elanco is working alongside the U.S. animal health industry to help them fight against this parasite, offering a portfolio of options for pets and livestock that can help treat New World screwworm larvae infestations.

Available Elanco Treatment and/or Prevention Options 

Negasunt Powder and Tanidil will be available only through the U.S. Animal Plant Health and Inspection Service (APHIS) and its National Veterinary Stockpile. They will be distributed in coordination with state animal health officials and federally recognized tribal agencies. In the near future, APHIS will share additional information about the requirements for use, including tracking and reporting requirements and required safety and personal protective equipment.

As New World screwworm enters the United States, Elanco is committed to working alongside producers as they continuously evolve management practices and to help them implement prevention and treatment protocols to use the right product at the right time.

To learn more about Elanco’s ongoing efforts and historical perspective on New World screwworm, please visit our previous coverage:

• Elanco’s Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock 
• Elanco’s Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs 
• Elanco’s Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats 
• Elanco’s Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs 

To learn more about New World screwworm (NWS) using the following resources:

• USDA NWS Alert and Fact Sheet 
• NCBA NWS Resources 
• FDA Information for Veterinarians on NWS 

i USDA Confirms Presence of New World Screwworm in the United States | Animal and Plant Health Inspection Service 
ii “New World Screwworm.” www.aphis.usda.gov, www.aphis.usda.gov/livestock-poultry-disease/cattle/ticks/screwworm.

PM-US-26-1137

About Elanco Animal Health 
Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Indications for Credelio Quattro/Credelio Quattro-CA1 
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Credelio Quattro-CA1 is conditionally approved for the treatment of infestations caused by New World screwworm (NWS) larvae in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.

Important Safety Information for Credelio Quattro/Credelio Quattro-CA1 
Lotilaner, an ingredient in Credelio Quattro/Credelio Quattro-CA1, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro/Credelio Quattro-CA1 administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea.

Credelio Quattro-CA1 is conditionally approved by the FDA pending a full demonstration of effectiveness under application number 141-619. If you suspect that your dog is infested with NWS larvae, seek veterinary care immediately for treatment to include removal of larvae and appropriate wound care.

For complete safety information, please see the Credelio Quattro/Credelio Quattro-CA1 product label or ask your veterinarian.

Emergency Use Authorization of Credelio (lotilaner) Chewable Tablets for New World Screwworm (NWS) 

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) chewable tablets for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Credelio is not approved for this use.

Credelio (lotilaner) is approved for other uses in dogs and puppies.

For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.

Limitations of Authorized Use 
Credelio (lotilaner) chewable tablets is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) chewable tablets under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio 
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

Important Safety Information for Credelio 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS) 
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use.

Credelio CAT is approved for other uses.

For additional information on the EUA, please refer to the Credelio Cat NWS Fact Sheet.

Limitations of Authorized Use 
Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Indications for Credelio CAT 
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater.

Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater.

Important Safety Information for Credelio CAT 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian.

Emergency Use Authorization of Negasunt Powder (coumaphos, propoxur, and sulfanilamide topical powder) for New World Screwworm (NWS)

WARNING: Neurotoxicity. Read full Fact Sheet for complete information.

• Coumaphos and propoxur can cause neurotoxicity. May be fatal if swallowed. May be fatal if inhaled. Harmful if absorbed through skin. Causes moderate eye irritation. Do not breathe dust. Avoid contact with eyes, skin, or clothing.
• Use only with appropriate personal protective equipment (PPE): coveralls worn over long-sleeve shirt and long pants, shoes, socks, and protective eyewear; chemical-resistant gloves made of barrier laminate, butyl rubber (≥ 14 mils), nitrile rubber (≥14 mils), neoprene rubber (>14 mils), natural rubber (≥14 mils), polyethylene, polyvinyl chloride (PVC) ≥14 mils, or Viton (>14 mils); and a minimum of a NIOSH-approved elastomeric half mask respirator consisting of protection factor (PF) 10 fitted with organic vapor (OV) cartridges and combination R or P filters; or a NIOSH-approved gas mask with OV canisters; or a NIOSH-approved powered air purifying respirator with OV cartridges and combination HE filters.
• This product is toxic to mammals, birds, fish, and aquatic invertebrates.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product Negasunt Powder for the prevention and treatment of infestations caused by New World screwworm (Cochliomyia homnivorax) larvae (myiasis) in cattle, swine, goats, sheep, horses, donkeys, domestic hybrid equids, and captive wild, exotic, and zoo mammals. Negasunt Powder is not approved for this use.

For use by employees of federal, state, local, and federally recognized tribal agencies, and persons working under their authority and at their direction. Also for use by or on the order of a licensed veterinarian in NWS infested zones and adjacent surveillance zones as defined by the U.S. Department of Agriculture (USDA).

For additional information on the EUA and for complete safety information, please refer to the Negasunt Powder NWS Fact Sheet.

Limitations of Authorized Use 
It is a violation of federal law to use this drug product other than as directed in the authorized Fact Sheet.

Treated animals must not be slaughtered for human consumption within 28 days of the last treatment.

A milk discard time has not been established for this product; do not use in animals producing milk for human consumption.

A withdrawal period has not been established for this product in pre-ruminating calves; treated calves and calves born to treated cows must not be processed for veal.

Do not use in horses intended for human consumption. Do not use in domestic indoor pets (e.g., dogs, cats, rodents, rabbits) nor in residences. Do not use in birds. Do not use in free-ranging wildlife.

To avoid overexposure, each individual person cannot treat more than 3 large wounds (>2 inches diameter) a day or more than 30 small superficial wounds (≤2 inches diameter) a day (or an equivalent thereof) with Negasunt Powder or any other coumaphos-containing products.

Negasunt Powder is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Negasunt Powder under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner.

Federal law prohibits the extra-label use of this drug.

Additional Important Safety Information 
Not for use in humans. Keep out of reach of children. Only handlers wearing required PPE may be in the area during application. Do not apply in a confined, non-ventilated area; provide thorough ventilation. Call a poison control center or doctor immediately for treatment advice if Negusant Powder is swallowed, inhaled, on skin or clothing, or in eyes. Sulfonamides are contraindicated in animals that are hypersensitive to them and in animals with severe renal or hepatic impairment. For external use only on animals. Do not contaminate water, feed, troughs, feed handling equipment, or milk or meat handling equipment. Use with caution in very young, weak, or debilitated animals. In the case of overdose, treat with atropine sulfate or pralidoxine chloride (2-PAM) as soon as possible. The most common adverse reactions associated with organophosphate and carbamate toxicity in animals include frequent urination and defecation, muscle twitching, and watering eyes.

Important Information about Tanidil 
Tanidil™ is an unregistered product for distribution and use only under a Section 18 emergency exemption. The Section 18 labeling must be in the possession of the user at the time of pesticide application. This product may only be used to prevent or control New World screwworm in and on animal wounds on labeled animal host species.

For use only by federal, state, local, and federally recognized tribal agencies, and persons working under their supervision; personnel at quarantine stations and areas; veterinarians; veterinarians or certified applicators at livestock and game facilities, zoos, wildlife facilities, animal rehabilitation centers; and wildlife professionals.

Read the entire label. This product must be used strictly in accordance with this label’s precautionary statements and use directions, as well as with all applicable state and federal laws and regulations. Please visit the Tanidil fact sheet for more information.

Use Period: This exemption is effective on April 27, 2026 and expires on April 27, 2029. No applications of Tanidil may be made under the emergency exemption before its effective date or after its expiration date.

Credelio, Credelio Quattro, Negasunt, Tanidil, Catron, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2026 Elanco or its affiliates 
 

Laverstoke, Hampshire, UK, June 4, 2026 /3BL/ – The BOMBAY SAPPHIRE® Distillery has been recognised for its continued leadership in conservation and biodiversity protection as it announces its Silver recertification through Wildlife Habitat Council (WHC) Certification, powered by Tandem Global. 

The Hampshire-based distillery, which is owned by Bacardi, has held the Silver Certification continuously since 2023 – a milestone that made it the first spirits production site in the UK to achieve the standard. Established in 1989, WHC Certification continues to be the world’s only voluntary sustainability standard for businesses enhancing biodiversity and supporting conservation education on their sites.

Located on the banks of the River Test, a designated Site of Special Scientific Interest, the BOMBAY SAPPHIRE distillery continues to support local biodiversity through initiatives including wildflower planting for pollinators and the installation of fish and eel passes to help improve river connectivity and support native species migration. The renewed Silver Certification recognises the distillery’s ongoing work to protect and restore wetland and river habitats, alongside continued efforts in biodiversity monitoring and responsible water stewardship along one of the UK’s most environmentally sensitive waterways.

The distillery is a landmark of sustainable design from globally celebrated, visionary designer Thomas Heatherwick. Its design is rated “Outstanding” by BREEAM – the world’s leading sustainability assessment method for masterplanning – and more than 99% of its waste is recycled or converted into energy. Added to this, Bombay Sapphire is crafted using a unique blend of 10 botanicals from sustainably certified suppliers. 

Beyond its own biodiversity programmes, BOMBAY SAPPHIRE and the Laverstoke Distillery continue to champion broader environmental action. In late 2025, the site hosted the presentation of the 2025 E1 Blue Impact Championship, presented by BOMBAY SAPPHIRE. The award, from E1 – the world’s first all-electric raceboat Championship – recognises the team that delivered the strongest season-long contribution to protecting and restoring aquatic ecosystems, supporting E1’s mission to accelerate ocean conservation efforts.

“The BOMBAY SAPPHIRE Distillery has been carefully cultivated with sustainability in mind. Being a Grade II listed historic site as well as a Site of Special Scientific Interest, conservation and restoration have always been central to the distillery and its surrounding landscape. Consideration for the environment runs throughout our practices at BOMBAY SAPPHIRE; from the partners we choose, including becoming the Official Gin partner of the E1 Series – the world’s first all-electric race boat championship, to the team’s dedication to sustainable practices in the production of our gin,” says Rodolfo Nervi, Vice President Corporate Sustainability, Global Safety and Quality at Bacardi. “We are incredibly proud to retain the WHC Silver Certification, having become the first UK spirits production facility to receive the recognition in 2023. We look forward to continuing our work to support the local environment and deliver meaningful, measurable outcomes for the landscapes and waterways around us.”

The site also participates in the Anglers’ Riverfly Monitoring Initiative, working with local volunteers from the Watercress and Winterbournes Landscape Partnership Scheme to track invertebrate populations. This citizen science programme provides valuable long-term data on river health, helping guide conservation priorities and adaptive environmental management.

“BOMBAY SAPPHIRE Distillery is recognised as meeting the strict requirements of WHC Certification. Companies achieving WHC Certification, like Bacardi, are environmental leaders, voluntarily managing their lands to support sustainable ecosystems and the communities that surround them,” says Margaret O’Gorman, Chief Executive Officer, Tandem Global.

The distillery joins other Bacardi facilities globally that have achieved certification and recognition for environmental performance, including operations in Puerto Rico and Jacksonville, Florida, underscoring the company’s broader commitment to sustainability across its global footprint.

To learn more about how Bacardi is doing the right thing, visit www.bacardilimited.com/CS 

Enjoy BOMBAY SAPPHIRE® responsibly.

MEDIA CONTACT:

bacardi@mucklemediagroup.co.uk
T: +44 (0) 7411264860

spey.scot

NOTES TO EDITORS:

About BOMBAY SAPPHIRE Distillery

The BOMBAY SAPPHIRE Distillery, located at the historic Laverstoke Mill in Hampshire, offers visitors a unique glimpse into the world of gin production. Opened to the public in 2014, the distillery is renowned for its Vapour Infusion process and its iconic glasshouses, designed by Heatherwick Studios, which showcase the ten botanicals used in the gin. With a range of tours, tastings, and cocktail masterclasses, the distillery provides an immersive experience for gin enthusiasts. Visitors can also enjoy the onsite café, bar, and shop. 

About Bacardi Limited
Bacardi Limited, the world’s largest privately held international spirits company, produces, markets, and distributes spirits and wines. The Bacardi Limited portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, PATRÓN® tequila, GREY GOOSE® vodka, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, D’USSÉ® Cognac, ANGEL’S ENVY® American straight whiskey, and ST-GERMAIN® elderflower liqueur. Founded more than 164 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs approximately 8,000, operates production facilities in 10 countries and territories, and sells its brands in more than 160 markets. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on LinkedIn and Instagram.

About Tandem Global
Tandem Global (formerly Wildlife Habitat Council and World Environment Center) provides the know-how and the network to move business and the environment forward, together. They work across sectors and at all levels of organizations to facilitate long-term and lasting impact on all aspects of our natural world. Tandem Global connects leading thinking with practical solutions that positively impact climate, nature, and water – from field operations to boardrooms and beyond. Learn more at https://tandemglobal.org/